

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

NCT05824988

Status RECRUITING
Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (4)

- Culture-positive MAC lung disease
- MAC treatment at the Shanghai Pulmonary Hospital
- A regimen composed of at least the core drugs, i.e., macrolides, rifamycin and ethambutol, in doses not lower than recommended according to the ATS/ERS/ESCMID/IDSA and Chinese national guidelines
- Written informed consent

Exclusion (5)

- Pregnancy
- Confirmed mixed infection with mycobacterial species, including *M.tuberculosis* and other NTM species
- Ongoing with any antimycobacterial treatment for more than one month, including tuberculosis and NTM
- Patients admitted to the intensive care unit
- Off-label use for any study drugs, such as inhalation of amikacin

Locations (1 total)

Shanghai Pulmonary Hospital, Shanghai, China